Podcast gratuito
Not So Different: a Podcast from The Center for Biosimilars
Podcast de Not So Different: a Podcast from The Center for Biosimilars
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
Este podcast se puede escuchar gratuitamente en todos las plataformas y en la app de Podimo sin necesidad de suscripción.
Todos los episodios
96 episodiosS4 Ep22: Not So Different: Tactics for Increasing Patient and Provider Confidence in Biosimilars
To listen to part 1 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-biosimilar-companies-are-stepping-up-their-game-to-compete-against-originators].To listen to part 2 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-1-practice-is-addressing-biosimilar-concerns-over-savings-safety-and-efficacy].To learn more about building patient confidence in biosimilars, click here [https://www.centerforbiosimilars.com/view/what-should-educational-materials-include-to-instill-confidence-in-biosimilars-].To learn more about how education can improve patient confidence, click here [https://www.centerforbiosimilars.com/view/report-physician-patient-education-can-improve-biosimilar-acceptance].
10 oct 2021 - 4 min
S4 Ep21: Not So Different: How 1 Practice is Addressing Biosimilar Concerns Over Savings, Safety, and Efficacy
To listen to part 1 of this podcast, click here [https://www.centerforbiosimilars.com/view/how-biosimilar-companies-are-stepping-up-their-game-to-compete-against-originators].
To learn more about building physician confidence in biosimilars, click here [https://www.centerforbiosimilars.com/view/gary-lyman-md-details-what-needs-to-be-done-to-ensure-physician-confidence-in-biosimilars].
For more on how switching to biosimilars can impact budgets and savings, click here [https://www.centerforbiosimilars.com/view/budget-model-predicts-savings-for-switch-to-rituxumab-biosimilar-in-nhl-cll].
03 oct 2021 - 5 min
S4 Ep20: Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators
Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market.
We sat down with Kirollos Hanna, PharmD, the manager of Oncology Pharmacy at the University of Minnesota Medical Center, an associate editor for the Journal of the Advanced Practitioner in Oncology, and an assistant professor at the Mayo Clinic School of Medicine, to discuss what tactics biosimilar companies are using to better compete alongside originator manufacturers.
19 sept 2021 - 3 min
S4 Ep19: Not So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in Biosimilars
A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice.
We sat down with Gary Lyman, MD, MPH, an oncologist, hematologist, public health researcher, and long-time biosimilar advocate who has also helped develop guidelines in support of using biosimilars in the oncology space. We discussed what steps are needed to improve physician confidence in using biosimilars.
15 ago 2021 - 16 min
S4 Ep18: Not So Different: Should Biosimilar Variations Be Concerning?
To hear more from Paul on biosimilar issues, click here [https://www.centerforbiosimilars.com/view/part-1-panelists-suggest-more-groundwork-is-needed-for-indian-biologics-to-achieve-global-market-access] or here [https://www.centerforbiosimilars.com/view/part-2-panelists-advise-patterning-guidelines-on-international-standards].To read about Paul’s insight on the current issues in the Indian biosimilar market, click here [https://www.centerforbiosimilars.com/view/column-india-struggles-to-meet-international-biologics-standards].
01 ago 2021 - 4 min
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
MI TOC es feliz, que maravilla. Ordenador, limpio, sugerencias de categorías nuevas a explorar!!!
Me suscribi con los 14 días de prueba para escuchar el Podcast de Misterios Cotidianos, pero al final me quedo mas tiempo porque hacia tiempo que no me reía tanto. Tiene Podcast muy buenos y la aplicación funciona bien.
App ligera, eficiente, encuentras rápido tus podcast favoritos. Diseño sencillo y bonito. me gustó.
contenidos frescos e inteligentes
La App va francamente bien y el precio me parece muy justo para pagar a gente que nos da horas y horas de contenido. Espero poder seguir usándola asiduamente.
Disponible en todas partes
¡Escucha Podimo en tu móvil, tablet, ordenador o coche!
Un universo de entretenimiento en audio
Miles de podcast y audiolibros exclusivos
Sin anuncios
No pierdas tiempo escuchando anuncios cuando escuches los contenidos de Podimo.
Tu oferta:
Acceso ilimitado a todos los podcasts exclusivos
Sin anuncios
Descubre miles de audiolibros
Después de la prueba 4,99 € / mes. Sin compromiso